Judy's story sets a precedent for future research, and hopefully future cures
Dr. Rosenberg, who generally takes on patients with aggressive forms of cancer, is aware that the therapy is experimental and not entirely ready to be used on a large-scale level. “A lot of work needs to be done, but the potential exists for a paradigm shift in cancer therapy — a unique drug for every cancer patient — it is very different to any other kind of treatment,” he said. Still, he believes that the new immunotherapy could set the pace for treating different types of cancer down the line and Tom Misteli, director of cancer research at the U.S. National Cancer Institute, strongly agrees. “This is an illustrative case report that highlights, once again, the power of immunotherapy. If confirmed in a larger study, it promises to further extend the reach of this T-cell therapy to a broader spectrum of cancers,” said Misteli.